- Home
- EBTC vs PRTC Comparison
EBTC vs PRTC Comparison
Compare EBTC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- PRTC
- Stock Information
- Founded
- EBTC 1989
- PRTC 2015
- Country
- EBTC United States
- PRTC United States
- Employees
- EBTC N/A
- PRTC N/A
- Industry
- EBTC Major Banks
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- EBTC Finance
- PRTC Health Care
- Exchange
- EBTC Nasdaq
- PRTC Nasdaq
- Market Cap
- EBTC 446.9M
- PRTC 414.6M
- IPO Year
- EBTC 2005
- PRTC N/A
- Fundamental
- Price
- EBTC $38.82
- PRTC $16.78
- Analyst Decision
- EBTC
- PRTC Buy
- Analyst Count
- EBTC 0
- PRTC 1
- Target Price
- EBTC N/A
- PRTC $45.00
- AVG Volume (30 Days)
- EBTC 19.4K
- PRTC 2.5K
- Earning Date
- EBTC 04-17-2025
- PRTC 04-30-2025
- Dividend Yield
- EBTC 2.58%
- PRTC N/A
- EPS Growth
- EBTC 11.95
- PRTC N/A
- EPS
- EBTC 3.27
- PRTC 0.21
- Revenue
- EBTC $172,242,000.00
- PRTC $4,828,000.00
- Revenue This Year
- EBTC N/A
- PRTC $35.98
- Revenue Next Year
- EBTC N/A
- PRTC $115.38
- P/E Ratio
- EBTC $11.92
- PRTC $7.47
- Revenue Growth
- EBTC 7.98
- PRTC 44.98
- 52 Week Low
- EBTC $22.60
- PRTC $13.30
- 52 Week High
- EBTC $44.41
- PRTC $32.98
- Technical
- Relative Strength Index (RSI)
- EBTC 59.53
- PRTC 45.09
- Support Level
- EBTC $38.23
- PRTC $17.41
- Resistance Level
- EBTC $39.25
- PRTC $17.55
- Average True Range (ATR)
- EBTC 0.90
- PRTC 0.46
- MACD
- EBTC 0.40
- PRTC 0.01
- Stochastic Oscillator
- EBTC 88.52
- PRTC 40.40
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.